| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 69539-0020-92 | 69539-0020 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jul 2, 2018 | In Use | |
| 67046-1619-03 | 67046-1619 | HYDROXYUREA | HYDROXYUREA | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Dec 2, 2025 | In Use | |
| 70518-0916-01 | 70518-0916 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Dec 18, 2019 | In Use | |
| 69025-0131-01 | 69025-0131 | Abiraterone acetate | Abiraterone acetate | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Apr 11, 2023 | In Use | |
| 70518-3615-00 | 70518-3615 | HYDROXYUREA | HYDROXYUREA | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Jan 10, 2023 | In Use | |
| 00004-1101-75 | 00004-1101 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 30, 1998 | Dec 31, 2014 | No Longer Used |
| 42291-0073-60 | 42291-0073 | ABIRATERONE | ABIRATERONE ACETATE | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Apr 29, 2021 | In Use | |
| 82009-0140-60 | 82009-0140 | Abiraterone acetate | Abiraterone | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Jul 16, 2024 | In Use | |
| 80725-0810-10 | 80725-0810 | Hydroxyurea | HYDREA | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Sep 11, 2025 | In Use | |
| 69315-0164-01 | 69315-0164 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Jul 9, 2020 | In Use | |
| 53808-0411-01 | 53808-0411 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jul 1, 2009 | In Use | |
| 62135-0784-12 | 62135-0784 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct 16, 2023 | In Use | |
| 72205-0285-05 | 72205-0285 | Abiraterone acetate | Abiraterone | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | May 24, 2024 | In Use | |
| 76310-0017-50 | 76310-0017 | Amifostine | Ethyol | 500.0 mg/10mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Jan 1, 2020 | In Use | |
| 55390-0308-03 | 55390-0308 | Amifostine | Amifostine | 500.0 mg/10mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Apr 2, 2008 | Dec 31, 2018 | No Longer Used |
| 00310-4611-50 | 00310-4611 | Durvalumab | Imfinzi | 500.0 mg/10mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | May 1, 2017 | In Use | |
| 66220-0017-03 | 66220-0017 | Amifostine | Ethyol | 500.0 mg/10mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Aug 1, 2016 | Oct 31, 2020 | No Longer Used |
| 68152-0108-09 | 68152-0108 | Belinostat | Beleodaq | 500.0 mg/10mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Jul 21, 2014 | Nov 30, 2022 | In Use |
| 55150-0270-01 | 55150-0270 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/2.5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Aug 25, 2021 | In Use | |
| 55150-0270-99 | 55150-0270 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/2.5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Nov 20, 2023 | In Use | |
| 25021-0261-50 | 25021-0261 | Pemetrexed Disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Dec 15, 2024 | In Use | |
| 43598-0387-11 | 43598-0387 | Pemetrexed disodium | Pemetrexed disodium | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
| 60505-6066-00 | 60505-6066 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | May 31, 2024 | In Use |
| 00409-2188-01 | 00409-2188 | PEMETREXED | PEMETREXED | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jun 27, 2022 | In Use | |
| 68001-0544-41 | 68001-0544 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sep 1, 2022 | In Use |
Found 12250 results — Export these results
Home